{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:04:46Z","timestamp":1747181086809,"version":"3.40.5"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Ankylosing spondylitis is a chronic immune-mediated inflammatory arthritis. Interleukin-17A (IL-17A) inhibitors is recognized as a novel therapeutic target for ankylosing spondylitis. However, there is still a lack of high-quality research evidence regarding the issues. Therefore, we performed a protocol for systematic review and meta-analysis to evaluate the efficacy and safety of IL-17A inhibitors in patients with ankylosing spondylitis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This protocol will be conducted under the preferred reporting items for systematic reviews and meta-analyses protocols (PRISMA-P) guidelines. Furthermore, the study has been registered on PROSPERO (CRD42022375885). The following electronic databases will be searched regardless of language and publication status: Pubmed, MEDLINE, EMBASE, China Biomedical Database, China National Knowledge Infrastructure, VIP Database, and Wanfang Database. Cochrane \u201cbias risk\u201d tool is used to assess the bias risk of the quality of the included literature. Data synthesis and statistical analysis will be performed using the RevMan 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A synthesis of current evidence of IL-17A inhibitors for ankylosing spondylitis will be shown in this protocol.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This review can provide convincing evidence to help clinicians make decisions when dealing with ankylosing spondylitis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000032224","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T21:37:16Z","timestamp":1673559436000},"page":"e32224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of interleukin-17A inhibitors in patients with ankylosing spondylitis: A protocol for systematic review and meta-analysis"],"prefix":"10.1097","volume":"101","author":[{"given":"Mingguang","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Shangqiu, Shangqiu, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Shangqiu, Shangqiu, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Shangqiu, Shangqiu, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4352","authenticated-orcid":false,"given":"Weibing","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The First People\u2019s Hospital of Shangqiu, Shangqiu, Henan, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","first-page":"780","article-title":"Ankylosing spondylitis: an update.","volume":"42","author":"Golder","year":"2013","journal-title":"Aust Fam Physician"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.rdc.2017.04.006","article-title":"Genetics and the causes of Ankylosing Spondylitis.","volume":"43","author":"Hanson","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"52","DOI":"10.7748\/ns2013.12.28.16.52.e7807","article-title":"Ankylosing spondylitis: diagnosis and management.","volume":"28","author":"Bond","year":"2013","journal-title":"Nurs Stand"},{"key":"R5-20250504","first-page":"1303","article-title":"Ankylosing spondylitis and axial spondyloarthritis.","volume":"375","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.2147\/IJGM.S336314","article-title":"Hip replacement in ankylosing spondylitis patients with advanced hip involvement: factors associated with bilateral total hip arthroplasty.","volume":"14","author":"Li","year":"2021","journal-title":"Int J Gen Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/rheumatology\/ker194","article-title":"Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.","volume":"50","author":"Baraliakos","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10067-021-05679-7","article-title":"Ankylosing spondylitis risk factors: a systematic literature review.","volume":"40","author":"Hwang","year":"2021","journal-title":"Clin Rheumatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis.","volume":"14","author":"Taams","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.3390\/ijms21176401","article-title":"The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis.","volume":"21","author":"Tsukazaki","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"715510","DOI":"10.3389\/fimmu.2021.715510","article-title":"Targeting the Interleukin-23\/Interleukin-17 inflammatory pathway: successes and failures in the treatment of axial spondyloarthritis.","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2010.135889","article-title":"The Assessment in Spondyloarthritis International Society (ASAS) classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general: the spondyloarthritis concept in progress.","volume":"70","author":"Zeidler","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials.","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations.","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaut.2014.01.015","article-title":"The classification and diagnostic criteria of ankylosing spondylitis.","volume":"48-49","author":"Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis.","volume":"15","author":"Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","article-title":"Secukinumab: a review in ankylosing spondylitis.","volume":"79","author":"Blair","year":"2019","journal-title":"Drugs"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/1744666X.2019.1561281","article-title":"The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.","volume":"15","author":"Dubash","year":"2019","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:48:56Z","timestamp":1746334136000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":19,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032224","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,12,9]]}}}